['diabetes', 'diabetes mellitus, type 2']
['semaglutide', 'placebo']

        Inclusion Criteria: - For Japan only: Male or female, age above or equal to 20 years at the
        time of signing inform consent - Subjects diagnosed with type 2 diabetes and treated with
        diet and exercise for at least 30 days before screening - HbA1c 7.0 - 10.0 % (53 - 86
        mmol/mol) (both inclusive) Exclusion Criteria: - Female who is pregnant, breast-feeding or
        intends to become pregnant or is of child-bearing potential and not using adequate
        contraceptive method (adequate contraceptive measures as required by local regulation or
        practice) throughout the trial including the 5 week follow-up period. United Kingdom:
        Adequate contraceptive measures are defined as established use of oral, injected or
        implanted hormonal methods of contraception, placement of an intrauterine device or
        intrauterine system, barrier methods of contraception (condom or occlusive cap with
        spermicidal foam/gel/film/cream/suppository), male sterilisation (where partner is sole
        partner of subject), or true abstinence (when in line with preferred and usual lifestyle) -
        Any chronic disorder or severe disease which, in the opinion of the investigator, might
        jeopardise subject's safety or compliance with the protocol - Treatment with any glucose
        lowering agent(s) in a period of 90 days prior to screening. An exception is short-term
        treatment (no longer than 7 days in total) with insulin in connection with inter-current
        illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value
        above or equal to 50 ng/L (pg/mL) - Personal or family history of medullary thyroid
        carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function
        defined as eGFR (estimated glomerular filtration rate ) below 30 mL/min/1.73 m^2 per
        modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary
        or cerebrovascular event within 90 days before randomisation - Heart failure, New York
        Heart Association class IV
      